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Abstract
The pharmacokinetic properties of three pyrrole-imidazole polyamides of similar size and Py-Im
content but different shape were studied in mouse. Remarkably, hairpin and cyclic oligomers
programmed for the same DNA sequence 5’-WGGWWW-3’ displayed distinct pharmacokinetic
properties. Furthermore, the hairpin 1 and cycle 2 exhibited vastly different animal toxicities.
These data provide a foundation for design of DNA binding Py-Im polyamides to be tested in
vivo.
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INTRODUCTION
Aberrant regulation of gene expression can result in a diseased state such as
autoimmunity,1–4 or cancer.5,6 The ability to alter transcriptional profiles in a temporal
fashion with small molecules could therefore possess value in the development of novel
therapeutic strategies. Pyrroleimidazole (Py-Im) polyamides represent a class of
programmable DNA minor groove binders with high affinities and specificities.7–10 While
their applicability to modulate gene expression in cell culture has been studied,11–17 it is
important to transition Py-Im polyamides to in vivo experiments. Although there are several
examples to this end,18,19 baseline understanding of in vivo properties must be provided
before the viability of Py-Im polyamides as modulators for specific disease models can be
investigated. We have shown previously that hairpin and cycle Py-Im polyamides can be
constructed which bind the same sequence of DNA in the minor groove. As we progress
from chemistry to biology, the question arises whether molecules of similar size and similar
function but different shape have different properties regarding trafficking in a living mouse.
Here we report the impact of structural modifications on mouse pharmacokinetics of the Py-
Im polyamides 1–3 (Fig. 1), employing either the intraperitoneal (IP) or the subcutaneous
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(SC) injection route. Mouse toxicity data associated with the hairpin 1 and cycle 2 are
presented. The interest in the polyamides 1–3, all targeting the genomic sequence 5’-
WGGWWW-3’, stems from our recent investigation that showed the utility of 1 to modulate
NF-κB dependent gene expression in cell culture.16
RESULTS
Py-Im polyamides were synthesized following established protocols (Fig. S1). The initial set
of in vivo experiments compared the plasma levels of the Py-Im polyamides 1–3 as
observed 1.5 h following an IP injection (120 nmol / animal; Fig. 2). The concentration of
hairpin 1 amounted to 13.8 µM, corresponding to 23 % of the injected compound, if a blood
volume of 2 mL per animal is assumed. The plasma levels of cycle 2 were found to be
significantly lower with 3.9 µM (6.5 % of injected compound). Most surprisingly, the
dication cycle 3, which is closely related to monocation 2, was only observed at about 0.7
µM in plasma, which would correspond to 1.2 % of the injected compound. The levels of 3
are approximated because the concentration was close to the detection limit of the HPLC
instrument. Control extractions from serum yielded extraction efficiencies of 100 (±4) %
(1), 84 (±2) % (2) and 58 (±3) % (3). This implies slightly higher blood levels of 2 (4.6 µM)
and 3 (ca. 1.2 µM).
We followed up with a more extensive pharmacokinetic analysis of the Py-Im polyamides 1
and 2 (Fig. 3) that displayed favorable accumulation in plasma at 1.5 h. Injection of 1 by the
IP route with subsequent blood withdrawals at different time points showed a rapid build-up
of the compound in plasma. The maximum of 14.8 µM was observed at 1 h post injection,
followed by a fast decline and a complete disappearance of the compound from circulation
within 24 h. Subcutaneous (SC) injection resulted in a slower elimination of the compound
and a somewhat more shallow curve overall (10.4 µM peak at 3 h post injection; Fig. 3A),
although again, no compound was detected 24 h post injection.
The circulation profile of cycle 2 was strikingly different (Fig. 3B). The initial plasma
levels, measured 1.5 h post injection, were substantially lower than those observed with
hairpin 1. Most interestingly, the compound remained in the bloodstream at micromolar
levels throughout the experiment and was still readily detectable 48 h post injection (0.8 µM
following IP and 2.1 µM following SC injection). An attempt was made to obtain the 72 h
time point; however, acute toxicity to the mice was observed. The animals began losing
weight, appeared lethargic and had to be euthanized for humane purposes.
The adverse reaction of animals to cycle 2 but not hairpin 1 merited further investigation.
Animal weight was used as a proxy for body condition with weight loss of over 15 % being
considered an endpoint criterion for the mice. The polyamide 1 was studied first (Fig.
4A,B). We found that the compound could be injected by either IP or SC at 120 nmol per
animal per injection over the course of two weeks without an adverse reaction (six injections
overall). Given the acute toxicity of cycle 2 at 120 nmol per animal, the corresponding
prolonged exposure experiments were conducted at a lower dosage. The dosing regimen was
scaled in line with dilution factors typically used in our cell culture experiments.
Administration of 30 nmol of 2 per animal (IP or SC, see Fig. 4C,D) alleviated the
symptoms of acute toxicity, i.e. the mice did not appear lethargic and displayed no
unwillingness to ambulate when gently touched. However, critical weight loss became
observable beginning with day 4. The animals typically reached their endpoints within a
week. This is a profound difference to the hairpin polyamide 1, which was tolerated at a
total of 720 nmol over two weeks without any obvious health impediment to the animals.
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DISCUSSION
The hairpin Py-Im polyamide 1 was detectable in plasma at peak concentrations of 14.8 µM
and 10.4 µM, following IP and SC injection, respectively. The drop in circulating levels of 1
was more rapid following IP than SC injection, but the polyamide was not detectable after
24 h for both routes (Fig. 3A). These findings can be compared to recent studies of rat
pharmacokinetics of the hairpin polyamides Ac-Im-Py-Py-γ-Im-Py-Py-β-Dp (compound
1035) and Ac-Py-Py-β-Py-Im-Py-γ-Py-Py-Py-β-Im-Py-β-Dp (compound 1666) following
intravenous (IV) injection.19,20 Matsumoto and co-workers reported rat plasma levels drop
to low percent over 3 h for both Py-Im polyamides. Because the molecules were
administered intravenously, there was no plasma level buildup characteristic for IP and SC
injections as we observed for 1. The highest plasma levels of both 1035 and 1666 were
determined at the earliest measured time points. Overall the clearance rates of 1035 and
1666 from rat plasma appear higher than what we observed for the hairpin 1. However,
because of difference in animal model (mouse vs rat), administration route (IP and SC vs
IV) and compound architecture, only qualitative comparisons can be made.
The cyclic polyamides 2 and 3, which differ in charge, exhibited lower plasma levels than
the hairpin polyamide 1, suggesting that molecular shape is a determinant for the
pharmacokinetics of Py-Im polyamides. The macrocycles 2 and 3 are less flexible than the
hairpin 1. Along with the charge difference between 2 and 3, this could result in altered
interstitial tissue penetration rates, clearance rates by the reticuloendothelial system and
adsorption propensities onto plasma proteins or the vascular endothelium. The prolonged
circulation times of the monocationic macrocycle 2, as opposed to the hairpin 1, are in
agreement with the recent findings made by Nasongkla et al who compared the
pharmacokinetic profiles of linear and cyclic polymers with unrelated composition.21 The
phenomenon was ascribed to the differential ability of the molecules to traverse kidney
nanopores. The difference in overall charge is a possible origin of the contrast between the
pharmacokinetic properties of the macrocycles 2 (monocationic) and 3 (dicationic). Charge
effects on pharmacokinetics and bioavailability of oligomers and proteins with otherwise
similar steric requirements have been previously reported.22–24
The sharp contrast in mouse toxicity of the hairpin 1 and the cycle 2 is potentially rooted in
the distinct blood circulation profiles of the two molecules. However, other contributing
forces, such as the existence of toxic metabolites of cycle 2 but not hairpin 1, cannot be
ruled out at this time.
CONCLUSIONS
In this investigation we compared the pharmacokinetic properties of the Py-Im polyamides
1–3. While possessing an identical heterocyclic eight-ring framework, the chemical
variations among these compounds were sufficient to give rise to three distinct
pharmacokinetic profiles in a mouse model. The hairpin polyamide 1 had a rapid
bloodstream accumulation / excretion profile, while cycle 2 could circulate in animals for at
least 48 h. The dicationic macrocycle 3 exhibited substantially lower plasma level than its
monocationic analog 2. A stark contrast was observed between the toxic profiles of 1 and 2:
while hairpin 1 was tolerated well by the animals, the injection of cycle 2 proved lethal. We
have shown previously that hairpin 1 is capable of modulating NF-κB dependent gene
transcription in cell culture. This study sets the stage for comparison of gene expression
profiles from cell culture experiments with tumor xenografts in animals. These results will
be reported in due course.
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EXPERIMENTAL SECTION
Polyamide synthesis
Kaiser oxime resin (LL, 200–400 mesh), benzotriazole-1-yl-oxytrispyrrolidinophosphonium
hexafluorophosphate (Py-BOP), and Boc-4-aminobutanoic acid were purchased from
Novabiochem. All other reagents were purchased from Sigma-Aldrich. Preparative HPLC
purification was performed on an Agilent 1200 Series instrument equipped with a
Phenomenex Gemini preparative column (250 × 21.2 mm, 5µm) with the mobile phase
consisting of a gradient of acetonitrile (MeCN) in 0.1% CF3CO2H (aqueous). Analytical
HPLC analysis was conducted on a Beckman Gold instrument equipped with a Phenomenex
Gemini analytical column (250 × 4.6 mm, 5µm), a diode array detector, and the mobile
phase consisting of a gradient of MeCN in 0.1% CF3CO2H (aqueous). Polyamide
concentrations were measured by UV analysis on a Hewlett-Packard model 8453 diode
array spectrophotometer in distilled and deionized water (ddH2O) using a molar extinction
coefficient (ε) of 69,500 M−1cm−1 at 310 nm. Matrix-assisted, LASER desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry was performed on an Applied Biosystems
Voyager DE-Pro spectrometer using α-cyano-4-hydroxycinnamic acid as the matrix.
ImImPyPy-(R)α-H2Nγ-PyPyPyPy-(+)-IPA, 1. Compound 1 was synthesized using
previously described methods. In brief, the Py-Im sequence was built on Kaiser oxime resin
and subsequently cleaved with 3,3’-diamino-N-methyldipropylamine.16,25 The crude
compound was precipitated with Et2O, dried and subjected to isophthalic acid conjugation
using standard PyBOP coupling conditions. The resultant mixture was deprotected (99 %
TFA, 1 % Et3SiH, 10 min) and purified by preparative reversephase HPLC, affording the
final product in 16 % overall yield (20 µmol). Compound purity was confirmed by analytical
HPLC (Fig. S3) and MALDI and was in agreement with previously published data.16
cyclo-(-ImImPyPy-(R)β-H2Nγ-PyPyPyPy-γ-), 2. Compound 2 was synthesized using
previously described methods. In brief, the Py-Im sequence was built on Kaiser oxime resin
and subsequently cleaved with DBU to give the precursor compound NH2-γ-ImImPyPy-
(R)β-NHCBzγ-PyPyPyPy-OH.16,25 Following purification by preparative HPLC, the
precursor was subjected to cyclization conditions using diphenyl phosphoryl azide and N,N-
diisopropylethylamine in DMF.26 The DMF was then removed by rotary evaporation, and
the residue was repeatedly precipitated from cold diethyl ether to remove all traces of base.
The isolated residue was submitted to deprotection conditions using a mixture of
trifluoroacetic acid and trifluoromethanesulfonic acid,27 and polyamide 2 was then purified
by preparative HPLC (0.7 % overall yield; 2.6 µmol). The key synthetic steps are
schematized in Fig. S1. Compound purity was confirmed by analytical HPLC (Fig. S3) and
MALDI (calc'd for M+H 1164.5, found 1164.9).
cyclo-(-ImImPyPy-(R)β-H2Nγ-PyPyPyPy-(R)β-H2Nγ-), 3. Compound 3 was synthesized as
above, replacing the final boc-4-aminobutanoic acid (γ) residue with a (R)-4-(Boc-
amino)-3-(Z-amino)butyric acid residue. Polyamide 3 was purified by preparative HPLC
(3.1% yield; 1.7 µmol). The key synthetic steps are schematized in Fig. S1. Compound
purity was confirmed by analytical HPLC (Fig. S3) and MALDI (calc'd for M+H 1179.5,
found o1179.9).
Animal experiments: General mouse handling
All experiments were performed in C57/BL6 mice between 8 and 12 weeks of age. The
animals were obtained through the Jackson Laboratory. All compounds were injected as 4:1
PBS/DMSO solutions at 200 µL per injection (U-100 insulin syringes, UltiCare). No
precipitate formation was observable in any of the experiments. Blood was collected by
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retro-orbital withdrawal, using heparinized 75MM hematocrit tubes (Drummond). During
blood collection the animals were anesthetized with 2–5 % isoflurane. Their breathing
frequency was monitored and not allowed to drop below 1 s−1, adjusting the isoflurane
levels accordingly. When the animals reached their endpoints, they were euthanized by
asphyxiation in a CO2 chamber.
Animal experiments: Pharmacokinetic analyses
Experiments were conducted in groups of four C57/BL6 mice. Plasma was obtained by
centrifugation of the collected blood at 6 × 103 × g for 5 min. The supernatant was isolated,
typically yielding approximately 50 µL mouse serum. The samples from the four replicate
mice were combined at 5 µL / sample, yielding 20 µL combined plasma that was then treated
with 40 uL MeOH, vortexed and centrifuged at 1.6 × 104 × g for 5 min. Fifty µL of the
supernatant were isolated and combined with one equivalent of the HPLC loading solution
(4:1 water/acetonitrile acidified with 0.08 % trifluoroacetic acid). Boc-Py-OMe (4, Fig. S2)
was employed as an internal standard to ensure the reproducibility of HPLC injections.
Analytical HPLC analyses were conducted on a Beckman Gold instrument equipped with a
Phenomenex Kinetex C18 analytical column (100 × 4.6 mm, 2.6 µm, 100 Å) and a diode
array detector. The mobile phase consisted of a gradient of acetonitrile (MeCN) in 0.1% (v/
v) aqueous CF3CO2H (5% to 60% MeCN at 2.0 mL/min over 12.5 min). Peaks were
detected and integrated at 310 nm absorbance using the Karat32 software. Sample
concentrations were determined through interpolation against a standard curve of
concentration vs. peak area generated using compound 1 (Fig. S4). Injection reproducibility
was below 15 % error for both IP and SC (see Fig. S5 and Table S1 for standard deviations).
Determination of the extraction efficiency from mouse plasma
All experiments were conducted using C57/BL6 mouse plasma (GeneTex). The plasma was
freshly centrifuged to remove residual particles prior to use. DMSO stock solutions of
polyamides 1– were made at 1.5 mM concentrations. To an eppendorf tube containing 198
µL mouse plasma 2 µL of a stock solution were added, the mixture vortexed and allowed to
incubate for 15 min. Two separate batches of 20 µL were then taken and treated with 40 µL
methanol each, followed by vigorous vortexing and centrifugation at 16000 × g for 5 min.
From each of the samples 50 µL supernatant were withdrawn and combined, followed by the
addition of 80 µL aqueous 0.01 % trifluoroacetic acid and the reference standard in 20 µL
acetonitrile. The thus obtained sample was injected onto the analytical HPLC in technical
duplicate at 40 µL per injection. To obtain the maximum expected values, the 1.5 mM stock
solutions were diluted 1:6 (DMSO) to mimic the dilution coefficient resulting from the
plasma workup. Two µL of the resultant DMSO solution were added to 178 µL aqueous 0.01
% trifluoroacetic acid, followed by the reference standard in 20 µL acetonitrile. The sample
was then injected onto the analytical HPLC in technical duplicate at 40 µL per injection.
Each extraction experiment was conducted in triplicate to obtain averaged values and
standard deviations.
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Figure 1.
Chemical structures and circle-stick models of Py-Im polyamides 1, 2 and 3. Open circles
represent pyrroles and closed – imidazoles. For key synthetic steps see Fig. S1.
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Figure 2.
Plasma levels of the compounds 1–3 (A–C, respectively) measured 1.5 h post intraperitoneal
(IP) injection into C57/BL6 mice (120 nmol per animal; 4 animals per group). HPLC traces
shown (4 as internal reference standard, see Fig. S2 for chemical structure).
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Figure 3.
Plasma levels of the polyamide 1 (A) and 2 (B) as per cent of reference standard 4 (HPLC).
IP injections indicated with filled and SC with open circles. All injections at 120 nmol /
animal in C57/BL6 wild type mice; 4 animals per group, exceptions indicated as N = 3 (***)
and N = 2 (**).
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Figure 4.
Mouse weights in response to treatment with polyamide 1 (A,B) and 2 (C,D). Injections at
given concentrations are indicated with arrows. All injections were done in C57/BL6 wild
type mice, 4 animals per group. Each curve represents the weight of an individual animal.
Raskatov et al. Page 10
J Am Chem Soc. Author manuscript; available in PMC 2013 May 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
